What are considerations for use of epoprostenol in special populations?

There are no adequate, well-controlled studies of the abeyant aftereffect of alloyed epoprostenol in abundant humans. In abundant animals, studies of connected infusions of epoprostenol sodium application doses college than commonly used in bodies has appear no problems with fetal bearing defects or miscarriage. Alloyed epoprostenol currently carries an FDA allocation of “B” in abundance and should be used during abundance if the account is acquainted to outweigh any risk.

Safety and ability in pediatric patients has not been established. Epoprostenol has been used in children. However, analytic studies of epoprostenol did not cover acceptable numbers of patients 16 years of age and beneath to actuate its assurance and ability in children.

Clinical studies did not cover a acceptable amount of patients over age 65 to actuate either assurance or ability for this age group.

Epoprostenol approval appears to be bargain in patients with alarmist insufficiency. This may aftereffect in decreased tolerability. Patients with balmy or abstinent alarmist dearth may be started at lower antecedent doses and may be added acute to dosage increases. Epoprostenol has not been advised in astringent alarmist insufficiency.

Epoprostenol has not been evaluated in patients with broken branch function. Since epoprostenol is mainly excreted through the kidney, bargain biologic approval may potentially aftereffect in added acknowledgment to epoprostenol and decreased tolerability. Likewise, the aftereffect of dialysis is unknown.